View Now | 2022 RDCA-DAP Workshop, September 13-14
Since its launch in 2019, the Rare Disease Cures Accelerator-Data and Analytics Platform initiative (RDCA-DAP®) has established itself as the leading platform to accelerate rare disease treatment innovation.
Join us this September as we bring rare disease stakeholders together for next-level platform demonstrations and case studies, industry expert presentations, panel discussions and more.
Attendees of the 1.5-day workshop, including patients, providers, researchers, clinicians, biopharmaceutical companies, regulatory reviewers and scientists, will leave with an understanding of:
- RDCA-DAP’s current and future impact on drug development in rare diseases from the perspectives of patients, regulators and industry partners
- How RDCA-DAP is unique in supporting multiple data and analysis-types across rare diseases
- The critical importance of building a rare disease community that works together to share optimal data and generate actionable solutions for the benefit of all rare disease patients
The Rare Disease Cures Accelerator-Data and Analytics Platform is an FDA-funded initiative with the goal of accelerating therapy development across rare diseases. The platform serves as a centralized and standardized infrastructure to host and share rare diseases data, to support and accelerate rare disease innovation.
We look forward to your participation!
For more information, visit: https://c-path.org/programs/rdca-dap/
Critical Path Institute is supported by the Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS) and is 55% funded by the FDA/HHS, totaling $17,612,250, and 45% funded by non-government source(s), totaling $14,203,111. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.
